Intercept management will also be presenting at the following investor conferences:
LEERINK Partners7th Annual Global Healthcare Conference on February 15, 2018at 2:00 p.m. Eastern Time
RBC Capital Markets Global Healthcare Conferenceon February 21, 2018at 10:00 a.m. Eastern Time
- 38th Annual
Cowen Health Care Conferenceon March 12, 2018at 2:10 p.m. Eastern Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in
CONTACT: For more information about
Media inquiries: email@example.com
Investor inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.